Author: slightbourne@noblecapitalmarkets.com

CoreCivic, Inc. (CXW) – Noble Virtual Conference Highlights

Posted on by slightbourne@noblecapitalmarkets.com


Monday, June 09, 2025

CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that serve the public good through high-quality corrections and detention management, a network of residential and non-residential alternatives to incarceration to help address America’s recidivism crisis, and government real estate solutions. We are the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and believe we are the largest private owner of real estate used by government agencies in the United States. We have been a flexible and dependable partner for government for nearly 40 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Noble Virtual Conference. CoreCivic CFO David Garfinkle and Vice President Finance Brian Hammonds presented at the Noble Virtual Conference. Highlights included increased demand, long-term trends, and return of capital. A rebroadcast is available at https://www.channelchek.com/videos/corecivic-cxw-noble-capital-markets-virtual-conference-replay

Increased Demand. As regular readers know, CoreCivic has seen increased demand for its services from ICE. The Company already has received new awards for beds and expects to re-open currently idled facilities for ICE. Increased occupancy could drive significant earnings growth. Occupancy in 1Q25 was 77%, still below the low 80% range in 2018/19. The Company showed various illustrative potential for increased demand that could add $73-$131 million of additional NOI.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Wall Street Gains as U.S.-China Trade Talks Spark Investor Optimism

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Stocks rose Monday as U.S. and Chinese officials met in London to address trade tensions and discuss resuming critical mineral exports.
– Semiconductor and Chinese tech stocks outperformed, with major gains from Qualcomm, AMD, and Alibaba amid optimism over eased restrictions.
– Investors await key inflation data later this week, while the S&P 500 continues to approach record highs despite lingering tariff uncertainties.

Stocks climbed on Monday as investors closely monitored renewed trade negotiations between the United States and China. The diplomatic meeting, held in London, marked another key step in the ongoing effort to ease tensions between the world’s two largest economies.

The S&P 500 rose 0.3%, while the Nasdaq Composite added nearly 0.4%. The Dow Jones Industrial Average was also higher, gaining 84 points, or 0.2%, by the end of the trading session.

Representatives from both countries met to resolve outstanding trade issues, including the flow of critical mineral exports. The U.S. delegation included Treasury Secretary Scott Bessent, Commerce Secretary Howard Lutnick, and Trade Representative Jamieson Greer. Discussions centered around verifying China’s commitment to restoring exports of rare earth elements, which are essential for electronics and clean energy technologies.

This round of talks follows a recent phone conversation between President Donald Trump and Chinese President Xi Jinping. In that call, both leaders agreed to pause tariff escalations while negotiations progressed. The latest diplomatic push appears to be an attempt to move beyond high-stakes disputes and toward more sustainable trade cooperation.

Investors responded positively, especially in sectors with direct exposure to China and global supply chains. Semiconductor stocks rallied, with Qualcomm jumping over 4% after announcing its $2.4 billion acquisition of chipmaker Alphawave. Other chipmakers, including Advanced Micro Devices and Texas Instruments, also gained more than 4%. Nvidia saw more modest gains, while Chinese tech giant Alibaba advanced 2%.

The strength in semiconductors and Chinese equities reflects a broader investor belief that trade de-escalation could benefit high-growth sectors reliant on stable cross-border commerce. Market analysts noted increased appetite for risk, particularly in areas sensitive to trade dynamics.

However, not all sectors shared in Monday’s gains. Apple stock declined by 1.5% following the company’s keynote at its 2025 Worldwide Developers Conference. The event featured the first major iOS redesign since 2013, but investors appeared underwhelmed by the announcements.

Looking ahead, inflation remains a key concern for markets. The Consumer Price Index (CPI) is scheduled for release on Wednesday, followed by the Producer Price Index (PPI) on Thursday. These data points will help clarify whether current tariffs are feeding through to consumer and producer prices — a key consideration for Federal Reserve policy decisions in the months ahead.

Despite lingering uncertainties, Wall Street’s mood remains cautiously optimistic. Last week, all three major indexes posted their second consecutive weekly gains. The S&P 500 even closed above the 6,000 mark for the first time since February, now less than 3% from its all-time high. Many investors appear to be looking past short-term trade noise and focusing instead on a more resilient and potentially stimulative economic environment.

U.S. Labor Market Adds 139,000 Jobs in May as Unemployment Holds Steady at 4.2%

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– U.S. added 139,000 jobs in May, topping forecasts; unemployment steady at 4.2%.
– Hourly earnings up 0.4% monthly, 3.9% annually.
– Job revisions and rising claims point to cooling momentum.

The U.S. labor market showed continued resilience in May, adding 139,000 nonfarm payroll jobs as the unemployment rate remained unchanged at 4.2%, according to data released Friday by the Bureau of Labor Statistics. The job gains exceeded economists’ expectations of 126,000, offering a modest sign of strength in an economy still grappling with new trade tensions and broader signs of slowing momentum.

While job growth in May beat forecasts, revisions to previous months suggest some underlying softness. April’s job gains were revised down to 147,000 from an initially reported 177,000, while March’s total was also lowered. Combined, the two-month revisions show the economy added 95,000 fewer jobs than previously thought.

“We’re seeing a softening in the labor market,” said Gregory Daco, chief economist at EY, in an interview with Yahoo Finance. “That’s undeniable. But it’s not a retrenchment in the labor market. And that’s what was feared.”

Despite the mixed signals, Wall Street responded positively to the report. The Dow Jones Industrial Average, S&P 500, and Nasdaq Composite each rose about 1% in early trading, as investors took comfort in the continued job growth and the prospect of stable interest rates from the Federal Reserve.

Wages continued to show strength in May, with average hourly earnings rising 0.4% month-over-month and 3.9% from a year ago. Both figures came in above economist expectations, suggesting that inflationary pressure from wage growth may persist. At the same time, the labor force participation rate dipped slightly to 62.4% from 62.6% in April, indicating fewer Americans are actively looking for work or are available to work.

The jobs report covered the week of May 12, capturing the early economic reaction to President Trump’s recently enacted 10% baseline tariffs on imports from various countries, as well as the initial phase of a 90-day pause in U.S.-China trade escalation. While the immediate labor market impact appears muted, economists warn that the inflationary effects of tariffs may begin to surface in the coming months.

“The May employment report was mixed but doesn’t alter our assessment of the labor market or the economy,” wrote Ryan Sweet, chief U.S. economist at Oxford Economics, in a research note. “We also remain comfortable with the forecast for the Federal Reserve to wait until December before cutting interest rates as the inflation impact of tariffs is still coming and will be more visible this summer.”

Other indicators released earlier in the week point to a labor market under increasing strain. ADP reported that the private sector added just 37,000 jobs in May—the lowest total in more than two years. In addition, initial weekly unemployment claims rose to their highest level since October 2024, while continuing claims hovered near a four-year high.

Taken together, the data suggest a labor market that, while no longer red-hot, remains stable for now. However, with trade policy uncertainties and inflation concerns on the horizon, economists will be closely watching for further signs of cooling in the months ahead.

MAIA Biotechnology (MAIA) – THIO Update Shows Another Increase In Overall Survival

Posted on by slightbourne@noblecapitalmarkets.com


Friday, June 06, 2025

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New THIO-101 Update Presented AT ASCO. MAIA presented updated data from its THIO-101 trial showing median overall survival increased as more patients advanced through treatment. Data presented showed a median overall survival of 17.8 months for patients receiving the combination of THIO and the PD-1 inhibitor, Libtayo (cemiplimab, a checkpoint inhibitor from Regeneron), an increase from 16.9 months reported in January 2025.

Survival Improved As More Patients Completed The Study. Updated data was presented at the American Society for Clinical Oncology (ASCO) 2025 Annual Meeting, with more patients treated for longer periods. The median overall survival reported was 17.8 months compared with the expected survival of 5.8 months for standard of care therapy. This was an improvement from 16.9 months (n=22 patients) reported in January 2025 and 10.6 months (n=19 patients) reported in August 2024.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

EuroDry (EDRY) – Sustained Market Weakness Weighs on Performance

Posted on by slightbourne@noblecapitalmarkets.com


Friday, June 06, 2025

EuroDry Ltd. was formed on January 8, 2018 under the laws of the Republic of the Marshall Islands to consolidate the drybulk fleet of Euroseas Ltd. into a separate listed public company. EuroDry was spun-off from Euroseas Ltd. on May 30, 2018; it trades on the NASDAQ Capital Market under the ticker EDRY. EuroDry operates in the dry cargo, drybulk shipping market. EuroDry’s operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company and Eurobulk (Far East) Ltd. Inc., which are responsible for the day- to-day commercial and technical management and operations of the vessels. EuroDry employs its vessels on spot and period charters and under pool agreements.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

First quarter financial results. Eurodry Ltd. reported an adjusted first quarter net loss of $5.7 million, or ($2.07) per share, compared to a loss of $3.2 million, or ($1.18) per share, during the same period last year. Adjusted EBITDA came in at a loss of $1.0 million, down from a gain of $2.1 million during the first quarter of last year. While revenue was slightly above our expectations, operating expenses were approximately $2.0 million higher than estimated due to increased repair costs. Overall, the quarterly results reflected the ongoing market challenges as charter rates remain near five-year lows due to challenging supply and demand trends.

Updating 2025 estimates. Based on the lower-than-expected first quarter results and management’s outlook, we are lowering our full year 2025 adjusted EBITDA and earnings per share (EPS) estimates to $9.3 million and ($3.79), respectively, down from $19.6 million and ($0.43). While we expect the second quarter to show a slight rebound, the weak market conditions are expected to persist and could constrain rates through the balance of the year.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Trump Pressures Fed for Deep Rate Cut, but Strong Jobs Data Dims the Odds

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Trump called for a full-point rate cut, but the Fed is unlikely to move after May’s better-than-expected jobs report.
– The U.S. economy added 139,000 jobs in May, with unemployment steady at 4.2%, easing fears of a labor slowdown.
– Fed officials remain focused on inflation, signaling no near-term rate cuts despite mounting political pressure.

President Donald Trump ramped up pressure on the Federal Reserve Friday, calling for a dramatic interest rate cut just as new data showed the U.S. labor market remains relatively strong. Trump’s plea came via a social media post in which he declared “AMERICA IS HOT” and pushed Fed Chair Jerome Powell to slash rates by a full percentage point—what he referred to as “rocket fuel” for the economy.

The timing of Trump’s demand, however, clashed with Friday’s release of the May jobs report, which showed the U.S. economy added 139,000 nonfarm payrolls—comfortably ahead of economists’ expectations of 126,000. Unemployment held steady at 4.2%, defying fears of a sharp slowdown. Wage growth also ticked higher, with average hourly earnings rising 0.4% month-over-month and 3.9% over the past year, indicating that worker demand remains solid despite broader concerns about economic deceleration.

Market watchers and economists were quick to point out that the report effectively shuts the door on the possibility of a rate cut at the Fed’s upcoming June meeting. “The labor market is not cracking yet, even though it is decelerating,” said Brij Khurana, a fixed income portfolio manager at Wellington Management. He noted that while earlier in the week, weak private payroll data from ADP raised questions about a potential cut, the stronger-than-expected government report all but “takes away June.”

Trump, who has repeatedly branded Powell as “Too Late” in an effort to blame the Fed chair for past inflation missteps, has increasingly turned the central bank into a political target. On Friday, he argued the Fed is “costing our country a fortune” by keeping borrowing costs elevated, citing the European Central Bank’s series of rate cuts as a model for what the U.S. should emulate.

But the Fed has held its benchmark rate steady in 2025 after lowering it by a full percentage point at the end of last year, citing uncertainty around economic policy and inflation risks. Recent commentary from Fed officials suggests the central bank is far more concerned with reining in inflation than stimulating employment. “I see greater upside risks to inflation at this juncture,” said Federal Reserve Governor Adriana Kugler, adding that current policy should remain unchanged unless inflation pressures abate.

Kansas City Fed President Jeff Schmid echoed those sentiments, warning that tariffs—some introduced by the Trump administration—could create further inflationary pressure. “While the tariffs are likely to push up prices, the extent of the increase is not certain,” Schmid noted, cautioning against prematurely loosening policy.

Still, some divergence within the Fed is emerging. Governor Chris Waller, speaking in South Korea last weekend, argued that any tariff-driven inflation would be temporary and should not alter the Fed’s long-term stance. “I support looking through any tariff effects on near-term inflation when setting the policy rate,” he said.

Yet with job gains still solid and inflation risks lingering, most analysts believe the Fed will remain on hold through the summer. Trump’s demand for a jumbo cut may resonate with some voters, but for now, the data simply doesn’t back him up.

Release – MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial

Posted on by slightbourne@noblecapitalmarkets.com

June 05, 2025 11:10am EDT

CHICAGO–(BUSINESS WIRE)– MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced a new partial response (PR) was identified in a patient after 20 months of treatment in its Phase 2 THIO-101 clinical trial evaluating ateganosine (THIO), sequenced with Regeneron’s immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC) who are resistant to immune therapy and chemotherapy. A partial response is defined as a decrease in tumor size of at least 30%.

“The patient remained on treatment and we observed stable disease for more than twenty months before the partial response was identified, highlighting the efficacy, safety and low toxicity of the treatment. Extended-term responses like this are not often seen in heavily pretreated patients in hard-to-treat diseases such as NSCLC, where the prognosis for the advanced-stage of the disease is typically poor,” said MAIA Chairman and CEO Vlad Vitoc, M.D. “We confirmed this response with a second scan, and we are highly confident that ateganosine could become an outstanding therapeutic alternative for third-line NSCLC patients.”

THIO-101 third line (3L) data cutoff from May 15, 2025, showed median overall survival (OS) of 17.8 months for the 22 NSCLC patients who received at least one dose of ateganosine in parts A and B of the trial. At the data cutoff, the patient with the longest survival in the trial had completed 32 cycles of therapy and had 24.3 months survival. Studies of standard-of-care (SOC) chemotherapy treatments for NSCLC in a similar setting have shown OS of 5 to 6 months.1

MAIA has announced the trial design for an expansion of its THIO-101 pivotal Phase 2 trial in NSCLC to assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous CPI treatment and chemotherapy.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

1 Girard N, et al. J Thorac Onc 2009;12:1544-1549.

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com

Source: MAIA Biotechnology

Released June 5, 2025

Release – MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer

Posted on by slightbourne@noblecapitalmarkets.com

June 05, 2025 8:04am EDT

Median overall survival (OS) from ateganosine (THIO) treatment extends to 17.8 months in latest data

CHICAGO–(BUSINESS WIRE)– MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, ateganosine (THIO), sequenced with Regeneron’s immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC) who are resistant to immune therapy and chemotherapy.

As of May 15, 2025, third line (3L) data showed median overall survival (OS) of 17.8 months for the 22 NSCLC patients who received at least one dose of ateganosine (the intent-to-treat population) in parts A and B of the trial. The updated analysis continues to demonstrate a 95% confidence interval (CI) lower bound of 12.5 months and a 99% CI lower bound of 10.8 months. The treatment has been generally well-tolerated to date in this heavily pre-treated population.1 Studies of standard-of-care (SOC) chemotherapy treatments for NSCLC in a similar setting have shown OS of 5 to 6 months.2-3

“It is gratifying to see that our treatment further extends lives for these hard-to-treat patient populations, especially in third-line NSCLC treatment where patients are most resistant to therapy,” said MAIA Chairman and CEO Vlad Vitoc, M.D. “This new benchmark of 17.8 months median OS is nearly triple the recognized SOC data for third-line NSCLC found in medical literature. We believe this is a substantial indicator of the potential ateganosine has to shift the NSCLC treatment landscape.”

MAIA’s multiple potential regulatory pathways for ateganosine could provide accelerated FDA approval and robust exclusivity in NSCLC, with a potential FDA decision as early as next year.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

1Details on safety can be found on the previously announced ASCO 2025 poster available on MAIA’s website.
2Girard N, et al. J Thorac Onc 2009;12:1544-1549.
3A.T. Freeman et al. Curr Oncol. 2020 May 1;27(2):76–82

Investor Relations Contact
+1 (872) 270-3518
ir@maiabiotech.com

Source: MAIA Biotechnology, Inc.

Released June 5, 2025

Release – Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Posted on by slightbourne@noblecapitalmarkets.com

June 5, 2025

PDF Version

  • Upfront fees and near-term development milestone payments totaling up to $11 million
  • Sales milestones of $150 million or more in first 10 years of commercialization
  • Royalties equaling 25% of net sales
  • Ocugen to manufacture and supply OCU400

MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the signing of a binding term sheet to negotiate and enter into a licensing agreement with a well-established leader in the pharmaceutical and healthcare sector in Korea, for exclusive Korean rights to OCU400—Ocugen’s novel modifier gene therapy for retinitis pigmentosa (RP).

Pursuant to the term sheet, under the license agreement Ocugen will receive upfront license fees and near-term development milestones equaling up to $11 million. The Company will be entitled to sales milestones of $1 million for every $15 million of net sales in Korea in addition to a royalty of 25% on net sales of OCU400 generated by Ocugen’s partner. Additionally, Ocugen will manufacture commercial supply of OCU400 under terms of a supply agreement.

There are an estimated 15,000 individuals in the Republic of Korea with RP. OCU400 provides the opportunity for our partner to help thousands of patients and become a leader in gene therapy in Korea.

“This regional licensing agreement is aligned with our business development strategy to partner with well-established companies in their respective countries and regions—leveraging their networks and know-how to treat as many RP patients as possible,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. “A regional approach preserves Ocugen’s rights to larger geographies to maximize total patient reach while also generating return for our shareholders.”

Additional details will be available once the definitive agreement between the parties is executed, which is expected to occur within the next 60 days.

Ocugen is currently advancing OCU400 through Phase 3 clinical development with a target Biologics License Application filing of mid-2026.

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies to address major blindness diseases and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the terms of the definitive license and timing of a definitive agreement or if a definitive agreement will be executed at all or the anticipated benefits to Ocugen of the definitive license agreement, qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that a definitive agreement for the license will be delayed or not executed at all, or that, if executed, it will not be on terms described above, the risk that contemplated license agreement, if executed, will not lead to the current anticipated benefits to Ocugen, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; the ability of OCU400 to perform in humans in a manner consistent with nonclinical or preclinical study data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com

Release – The GEO Group Announces It Has Entered Into a Purchase Agreement to Sell Company-Owned Lawton Correctional Facility in Oklahoma for $312 Million

Posted on by slightbourne@noblecapitalmarkets.com

June 5, 2025

PDF Version

BOCA RATON, Fla.–(BUSINESS WIRE)–Jun. 5, 2025– The GEO Group, Inc. (NYSE: GEO) (“GEO” or the “Company”) announced today that it has entered into a purchase agreement with the Oklahoma Department of Corrections for the sale of the GEO-owned Lawton Correctional Facility (the “Facility”) located in Lawton, Oklahoma for $312 million.

The sale of the Facility is expected to close on July 25, 2025, subject to the satisfaction of customary closing conditions, and GEO expects to transition Facility operations to the Oklahoma Department of Corrections simultaneously on July 25, 2025. GEO expects to use the net proceeds from the sale of the Facility to pay down debt and for general corporate purposes.

George C. Zoley, Executive Chairman of GEO, said, “The sale of our Company-owned Lawton Correctional Facility is expected to be a significant deleveraging event for our Company. We believe that this important transaction is representative of the intrinsic value of our Company-owned facilities, which total more than 52,000 beds. Our Management Team and Board of Directors remain focused on the disciplined allocation of capital to enhance long-term value for our shareholders.”

About The GEO Group
The GEO Group, Inc. (NYSE: GEO) is a leading diversified government service provider, specializing in design, financing, development, and support services for secure facilities, processing centers, and community reentry centers in the United States, Australia, South Africa, and the United Kingdom. GEO’s diversified services include enhanced in-custody rehabilitation and post-release support through the award-winning GEO Continuum of Care®, secure transportation, electronic monitoring, community-based programs, and correctional health and mental health care. GEO’s worldwide operations include the ownership and/or delivery of support services for 98 facilities totaling approximately 77,000 beds, including idle facilities and projects under development, with a workforce of up to approximately 18,000 employees.

Use of forward-looking statements
This news release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to the cautionary statements and risk factors contained in GEO’s filings with the U.S. Securities and Exchange Commission including its Form 10-K, 10-Q and 8-K reports. All forward-looking statements speak only as of the date of this news release and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements. Readers are strongly encouraged to read the full cautionary statements and risk factors contained in GEO’s filings with the U.S. Securities and Exchange Commission, including those referenced above. GEO disclaims any obligation to update or revise any forward-looking statements, except as required by law.

Pablo E. Paez, (866) 301 4436
Executive Vice President, Corporate Relations

Source: The GEO Group, Inc.

Cellebrite Acquires Corellium, Supercharging Mobile Security and Arm-Based Virtualization Capabilities

Posted on by slightbourne@noblecapitalmarkets.com

Cellebrite (NASDAQ: CLBT), a global leader in digital investigative solutions, announced on Thursday that it has entered into an agreement to acquire Corellium, a privately held innovator in Arm-based virtualization technology. The acquisition, valued at $170 million in cash with an additional $30 million tied to performance milestones, marks a significant expansion of Cellebrite’s capabilities in mobile vulnerability research, digital forensics, and security testing.

The deal brings together two powerhouses in digital investigation and device security, promising a new wave of innovation for both public and private sector customers. Corellium is known for its highly advanced virtualization software that allows users to create and interact with virtual iOS, Android, automotive, and IoT devices—without needing the physical hardware. This approach not only accelerates vulnerability detection and mobile penetration testing, but also enables development and security teams to conduct testing in a fully forensically sound environment.

Cellebrite interim CEO Thomas E. Hogan said the acquisition will help the company’s clients “secure both their communities and institutions,” calling Corellium’s platform “industry-unique.” He emphasized that the merger adds not just game-changing technology, but also top-tier talent in malware analysis and security research. “The combination of our respective talent and IP changes the game in the efficient securing and analysis of all Arm-based devices which are pervasive across a vast range of applications from cloud to edge,” Hogan said.

Chris Wade, founder and CTO of Corellium, will take on the role of Chief Technology Officer at Cellebrite following the acquisition. “With Cellebrite’s offerings, users have the blueprints—technical schematics of what’s on a device,” Wade said. “With Corellium, they can now virtually walk through the device, explore every room, and open every door safely and without altering a thing.”

The acquisition signals Cellebrite’s intent to significantly broaden its total addressable market. In the public sector, Corellium’s technology will be integrated into Cellebrite’s Digital Investigation Platform to support defense, intelligence, and law enforcement agencies in navigating increasingly complex mobile environments. On the enterprise side, Corellium’s virtualization capabilities are expected to expand Cellebrite’s presence beyond traditional eDiscovery use cases, enabling more robust DevSecOps and security workflows for mobile and embedded systems.

The deal is also drawing attention from the broader tech community. Mohamed Awad, SVP and GM of Infrastructure at Arm, praised Corellium’s contributions to the Arm ecosystem. “As AI continues to transform markets and deliver new experiences, the safety and security of our devices has never been more critical,” said Awad. “Corellium’s virtualization solutions leverage the unique footprint Arm has from cloud to edge.”

The transaction, expected to close this summer, is subject to approval from the Committee on Foreign Investment in the United States (CFIUS) and other standard closing conditions. Cellebrite plans to share more details about Corellium’s financial contribution following the completion of the deal.

J.P. Morgan Securities LLC served as exclusive financial advisor to Corellium.

Cellebrite also noted that it is nearing the conclusion of its search for a permanent CEO and expects to make an announcement before reporting its second-quarter 2025 results in mid-August.

Xcel Brands (XELB) – Positive Cash Flow Outlook Still In Tact

Posted on by slightbourne@noblecapitalmarkets.com


Thursday, June 05, 2025

Xcel Brands, Inc. 1333 Broadway 10th Floor New York, NY 10018 United States https:/Sector(s): Consumer Cyclical Industry: Apparel Manufacturing Full Time Employees: 84 Key Executives Name Title Pay Exercised Year Born Mr. Robert W. D’Loren Chairman, Pres & CEO 1.27M N/A 1958 Mr. James F. Haran CFO, Principal Financial & Accou

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q1 Results. First quarter results indicated a modest improvement from Q4, but it was a slow start to the year. First quarter revenues were $1.3 million, and the company reported an adj. EBITDA loss of $0.7 million from continuing operations. We believe the company is well positioned to benefit from a number of favorable developments, including the launch of new brands, contributions from Halston, and a lower cost base.

Positive outlook. The company indicated that it plans to be adj. EBITDA $1 million to $2.5 million positive for full year 2025 in spite of the potential impact of trade policies and disruption from headquarter consolidation at HSN and QVC. The outlook is supported by significant cost reductions that are expected to be at a run rate of $2.5 million per quarter and building royalty revenue from GIII and its Halston brand. Most of the trade policy uncertainty is focused on the second half of the year. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Euroseas (ESEA) – Increasing 2025 Estimates, Conference Highlights

Posted on by slightbourne@noblecapitalmarkets.com


Thursday, June 05, 2025

Euroseas Ltd. was formed on May 5, 2005 under the laws of the Republic of the Marshall Islands to consolidate the ship owning interests of the Pittas family of Athens, Greece, which has been in the shipping business over the past 140 years. Euroseas trades on the NASDAQ Capital Market under the ticker ESEA. Euroseas operates in the container shipping market. Euroseas’ operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. Euroseas employs its vessels on spot and period charters and through pool arrangements.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New M/V Emmanuel P time charter contract. Euroseas Ltd. secured a new time charter contract for its 4,250 twenty-foot-equivalent (TEU) intermediate containership, M/V Emmanuel P, for a minimum of 36 months to a maximum period of 38 months, at the option of the charterer, at a gross daily rate of $38,000. The new contract represents a significant improvement compared to the previous rate of $21,000 per day. Following the completion of a scheduled drydock and installation of energy saving devices, the new charter is expected to commence upon delivery of the vessel from the shipyard in the first half of September.

Agreement to sell the M/V Marcos. Euroseas Ltd. recently signed an agreement to sell the M/V Marcos V, a 6,350 twenty-foot-equivalent unit (TEU) intermediate containership, to an unaffiliated third party for $50 million. The vessel will be delivered to the buyer in October 2025. ESEA expects to recognize a gain of ~$8.5 million, or $1.20 per share. The vessel was acquired in the fourth quarter of 2021 for $40 million. During its ownership, Euroseas Ltd. realized more than five times its original equity investment.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.